Table 1 Patient data, first line chemotherapy and laboratory results of the whole patient collective, grouped into the patients matching our oligometastatic disease (OMD) criteria and those who do not
From: Proposal for a definition of "Oligometastatic disease in pancreatic cancer"
Oligometastatic disease (OMD) n = 10 | No oligometastatic disease (noOMD) n = 118 | Mann-Whitney U Test (p-value) | |
|---|---|---|---|
Sex | |||
Male (%) | 7 (70) | 73 (61) | |
Female (%) | 3 (30) | 47 (39) | |
Age upon diagnosis, median (minimum; maximum) | 65 (53;89) | 66 (30;84) | 0.945 |
Primary tumor: size [cm2], median (minimum; maximum) | 14.5 (4.4;21.6) | 12.0 (0.8;68.4) | 0.758 |
Primary tumor: max. diameter [cm], median (minimum; maximum) | 4.1 (2.4;9.0) | 4.0 (1.0;10.4) | 0.348 |
Primary tumor: Location | |||
Head, n (%) | 2 (20.0) | 53 (46.5) | |
Body, n (%) | 4 (40.0) | 17 (15.8) | |
Tail, n (%) | 4 (40.0) | 42 (37.7) | |
Chemo: First line | |||
None, n (%) | 0 (0) | 17 (14.2) | |
Gemcitabine, n (%) | 3 (30.0) | 38 (31.7) | |
Gemcitabine + Erlotinib, n (%) | 2 (20.0) | 13 (10.8) | |
Gemcitabine + nab-Paclitaxel, n (%) | 2 (20.0) | 19 (15.8) | |
FOLFIRINOX, n (%) | 0 (0) | 4 (3.3) | |
5-FU, n (%) | 0 (0) | 2 (1.7) | |
Gemcitabine + Afatinib, n (%) | 1 (10.0) | 12 (10.0) | |
Capecitabin + Erlotinib, n (%) | 0 (0) | 1 (0.8) | |
Ibrutinib/Placebo + nab-Paclitaxel + Gemcitabine, n (%) | 1 (10.0) | 8 (6.7) | |
NAPOLI, n (%) | 0 (0) | 1 (0.8) | |
Capecitabine, n (%) | 1 (10.0) | 2 (1.7) | |
FOLFOX, n (%) | 0 (0) | 1 (0.8) | |
Gemcitabine + nab-Paclitaxel + Afatinib, n (%) | 0 (0) | 2 (1.7) | |
Bilirubin level [mg/dL] BL, median (minimum; maximum) | 0.3 (0.2;1.7) | 0.6 (0.2;14.2) | 0.157 |
LDH [U/L] BL, median (minimum; maximum) | 209 (179;393) | 230 (13;1870) | 0.439 |
CRP [mg/L] BL, median (minimum; maximum) | 28 (4;65) | 11 (1;348) | 0.498 |
CA 19–9 [U/mL] BL, median (minimum; maximum) | 35 (2;885) | 978 (1;938,670) | 0.003 |
CEA [μg/L] BL, median (minimum; maximum) | 4 (2;80) | 11 (0;13,006) | 0.140 |